# NEUROONE MEDICAL TECHNOLOGIES Corp: Form 10-Q for the period ended Mar 31, 2020

- Company: [NEUROONE MEDICAL TECHNOLOGIES Corp](/companies/nmtc.md) (CIK 1500198)
- Form: 10-Q
- Filed: 2020-05-14
- Accepted by EDGAR: May 14, 2020, 20:20 ET
- Period: 2020-03-31
- Accession: 0001213900-20-012278
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1500198/000121390020012278/f10q0320_neuroonemed.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1500198/000121390020012278/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2020-01-01 to 2020-03-31 | $342.1k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2019-10-01 to 2020-03-31 | $843.9k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2020-01-01 to 2020-03-31 | −$1.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2019-10-01 to 2020-03-31 | −$3.2m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2020-01-01 to 2020-03-31 | −$1.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2019-10-01 to 2020-03-31 | −$6.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-01-01 to 2020-03-31 | −$0.10 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2019-10-01 to 2020-03-31 | −$0.43 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2019-10-01 to 2020-03-31 | −$2.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2019-10-01 to 2020-03-31 | $40.2k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2020-03-31 | $747.2k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-03-31 | $828.5k | us-gaap:AssetsCurrent |
| Total assets | at 2020-03-31 | $1.4m | us-gaap:Assets |
| Current liabilities | at 2020-03-31 | $6.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-03-31 | $6.6m | us-gaap:Liabilities |
| Short-term borrowings | at 2020-03-31 | $4.9m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2020-03-31 | −$5.2m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1500198/000121390020012278/f10q0320_neuroonemed.htm

Filed May 14, 2020.
Source: SEC EDGAR, the filing index for accession 0001213900-20-012278. Last ingested by Listed: Oct 24, 2026, 15:07 ET. No prices; not investment advice.
